Microwave thermotherapy is a type of ultrasound treatment in which body tissue is exposed to high temperatures. Focused ultrasound waves with high intensity damage and kill cancer cells or to make cancer cells more sensitive to the effects of radiation and certain anticancer drugs.
Examples for such treatments are the transurethral microwave thermotherapy (TUMT) and transurethral needle ablation (TUNA) that are used for benign prostatic hyperplasia.

See also High Intensity Focused Ultrasound and Ultrasound Therapy.

Ultrasound therapy uses high energy sound waves to treat different diseases. Historically, the use of ultrasonic waves in therapy began before the wide use as a diagnostic medical imaging tool. Dependend on the intensity, ultrasound therapy reach from the thermal effect used in physical therapy to the destruction of tissue with lithotripsy.

Types of ultrasound treatment:
See also Thermal Index, History of Ultrasound, Interventional Ultrasound, and B-Mode Acquisition and Targeting.

As far as ultrasound is concerned, 4D ultrasound (also referred to as live 3D ultrasound or 4B-mode) is the latest ultrasound technology - the fourth dimension means length, width, and depth over time. 4D Ultrasound takes 3D ultrasound images and adds the element of time to the progress so that a moving three-dimensional image is seen on the monitor. A 4D scan takes the same amounts of time as a 2D or 3D scan; the difference is the ultrasound equipment being used. One advantage of a 4D fetal ultrasound to a 2D-mode is that parents can see how their baby will generally look like. However, there are different opinions over the medical advantages.
To scan a 3D ultrasound image, the probe is swept over the maternal abdomen. A computer takes multiple images and renders the 3D picture. With 4D imaging, the computer takes the images as multiple pictures while the probe is hold still and a 3D image is simultaneously rendered in real time on a monitor.
In most cases, the standard 2D ultrasound is taken, and then the 3D/4D scan capability is added if an abnormality is detected or suspected. The 3D/4D sonogram is then focused on a specific area, to provide the details needed to assess and diagnose a suspected problem. A quick 4D scan of the face of the fetus may be performed at the end of a routine exam, providing the parents with a photo.

[This entry is marked for removal.]

From Acusphere Inc
AI-700 (trade name Imagify™) is an US contrast agent, usable for myocardial perfusion undergoing regulatory FDA approval. The synthetic polymers used in AI-700 (perflubutane polymer microspheres) do not break during the ultrasound imaging procedure. The used perfluorocarbon filling gas is less soluble in water and therefore has the propensity to stay inside the contrast agent particles. As a result, a higher concentration of gas is delivered to the myocardium over a longer period of time, thereby enabling AI-700 to target the broader application of myocardial perfusion assessment.
Imagify is a dry powder consisting of small, porous microparticles filled with perfluoropropane. These microparticles are made of a synthetic biodegradable polymer, called poly (D, L-lactide co-glycolide), or PLGA, that has been used in other drug delivery systems approved by the FDA.
The composition and structure of the phospholipid containing microparticles and the properties of the perfluorocarbon gas slow the rate at which the gas dissolves and prevent the microparticles from being quickly broken down. The powder is to suspend in sterile water and injected by a single intravenous injection prior to ultrasound imaging.

In 2009, Acusphere Inc received feedback from the Food and Drug Administration (FDA) to their New Drug Application (NDA) stating that another clinical trial would be required for U.S. approval, this one demonstrating that Imagify with ultrasound is superior to ultrasound without Imagify.
In June 2004, Acusphere entered into a Collaboration, License and Supply Agreement with Nycomed Danmark APS for the European development and marketing rights to Acusphere's lead product candidate AI-700.
Acusphere's focus will be on preparing the Marketing Authorization Application (MAA) for filing in Q4 2010, building upon the work that the previous partner, Nycomed, had done, in concert with the NDA.


In 2008 the FDA panel rejected the regulatory application for AI-700 (Imagify™) because of safety concerns.

From ALOKA Co., Ltd.;
'Veterinary portable ultrasound system:
The SSC-210 Vet is a price performance breakthrough in diagnostic imaging. The variable frame rate, up to 30 frames/sec., combined with dynamic focusing produces highly detailed images that can be optimized and frozen at the touch of a button. The push key controlled, linear distance calipers permit fast, accurate measurement of any structure within the two-dimensional image. The built-in digital scan converter let you output the image directly to a video recording system.'